Protection of β cells from autoimmune destruction potentially cures type 1 diabetes mellitus (T1D). During antigen presentation, interactions between cytotoxic T-lymphocyte antigen-4 (CTLA4) and B7 molecules, or programmed death 1 (PD1) and its ligand PDL1, negatively regulate immune responses in a non-redundant manner. Here we employed β-cell-targeted adeno-associated virus serotype 8 (AAV8)-based vectors to overexpress an artificial PDL1-CTLA4Ig polyprotein or interleukin 10 (IL10). β-Cell-targeted expression of PDL1-CTLA4Ig or IL10 preserved β-cell mass and protected NOD mice from T1D development. When NOD mice were treated with vectors at early onset of hyperglycemia, PDL1-CTLA4Ig or IL10 alone failed to normalize the early onset of hyperglycemia. When drug-induced diabetic mice received major histocompatibility complex (MHC)-matched allo-islets, with or without pretreatment of the PDL1-CTLA4Ig-expressing vector, PDL1-CTLA4Ig-expressing islets were protected from rejection for at least 120 days. Similarly, transplantation of PDL1-CTLA4Ig-expressing MHC-matched islets into mice with established T1D resulted in protection of allo-islets from acute rejection, although islet grafts were eventually rejected. Thus the present study demonstrates the potent immuno-suppressive effects of β-cell-targeted PDL1-CTLA4Ig overexpression against T1D development and allo-islet rejection. The gene-based simultaneous inhibition of PD1 and CTLA4 pathways provides a unique strategy for immunosuppression-free tissue/organ transplantation, especially in the setting of no established autoimmunity.
INTRODUCTION
Type 1 diabetes mellitus (T1D) is caused by autoimmune destruction of the insulin-producing β cells. The susceptibility to develop T1D has been linked to the human leukocyte antigen genotypes, DR and DQ, and to a lesser degree to other genes, including CTLA-4, PTPN22 and insulin-VNTR. 1 β-Cell-targeted autoimmune responses involve an expansion of auto-reactive CD4+ and CD8+ T cells, autoantibody-producing B cells and activation of the innate immune system. 2, 3 Continuing β-cell destruction results in progressive β-cell mass decline, ultimately leading to absolute insulin deficiency requiring life-long insulin therapy. 4 Additionally, fluctuating blood glucose levels often result in diabetes-associated complications, such as retinopathy, neuropathy and cardiorenal diseases. 4 Immunotherapy arresting the β-cell mass decline at early onset provides an opportunity for immune intervention to replenish β-cell mass. Indeed, earlier studies have demonstrated high doses of non-specific immune suppression, by anti-CD3 antibody, preserved C-peptide production in new-onset T1D. 5, 6 Unfortunately, recent phase III immunotherapy trials with CD3 antibody have failed to meet therapeutic end points. 7, 8 Transplantation of pancreatic islets has emerged as another promising therapy for T1D, offering a potential cure. For instance, the Edmonton protocol, first described by Shapiro et al., 9 has achieved long-term islet survival; 20% of islet recipients remained insulin-therapy-free at 5 years after transplantation. 9, 10 Over 50% of subjects showed favorable glycemic control, demonstrating the advantage of tight glucose regulation over the regular insulin replacement therapies. 11, 12 Recent studies have also shown improvements in primary efficacy, safety outcomes and insulin independence 3 years posttransplant. 11, 12 Despite such significant advances, 13 challenges have precluded the widespread use of islet transplantation. One major limitation is the requirement of lifelong immunosuppression. In the glucocorticoid-free Edmonton protocol, daclizumab is transiently used immediately after transplantation, while sirolimus (rapamycin) and tacrolimus (FK506) are given for life. However, these agents cause side effects, such as anemia, hyperlipidemia and renal toxicity. 14, 15 Additionally, commonly used immunosuppressants, calcineurin inhibitors (FK506 and cyclosporine) and rapamycin, have been linked to impaired islet function and insulin action, 16, 17 which may have a role in the difficulty of achieving long-term islet survival in transplant recipients. 18 During the T-cell receptor complex activation by an antigen presented on major histocompatibility complex (MHC) molecules, costimulation via interaction between B7 molecules on antigenpresenting cells and the coreceptor CD28 on T cells is required for optimal T-cell activation. 19 Cytotoxic T-lymphocyte antigen-4 (CTLA4) on T cells binds to B7 molecules on the antigenpresenting cells and attenuates the immune response. Similarly, interaction between the programmed cell death 1 (PD1) receptor on T cells and its ligand PDL1 on the antigen-presenting cells leads to negative regulation of immune responses. 20 Notably, CTLA4 and PD1 inhibitory pathways are non-redundant, 21 and PD1 and CTLA4 combination blockade has demonstrated synergistic effects on immune activation in peripheral immune tolerance. 22 Importantly, in a T1D immunotherapy trial, inhibition of the CTLA4 pathway by abatacept (CTLA4-Ig) delayed, but not blocked, the decline of β-cell function in recent-onset T1D. 23 In this study, we employ a non-pathogenic, highly β-cell-tropic adeno-associated virus serotype 8 (AAV8)-based vectors for β-celltargeted overexpression of PDL1, CTLA4Ig and interleukin 10 (IL10) transgenes. We assessed the effects of β-cell-targeted immunomodulation on T1D development and islet rejection in spontaneous autoimmune diabetes and matched islet transplantation models.
RESULTS AND DISCUSSION
Generation of a β-cell-targeted AAV vector expressing an artificial PDL1-CTLA4Ig polyprotein Previously, we and others have demonstrated efficient β-celltargeted gene delivery by AAV8 and AAV9 vector with rat insulin promoter sequences. 24, 25 We and others also found that AAV8 vector with a mouse insulin 2 gene (MIP2) promoter show robust, and β-cell-specific, transgene expression. 26 We therefore generated AAV8 vector expressing mCherry gene, under the control of MIP2 promoter. As shown in Figure 1a , intraperitoneal injection of the AAV8-MIP2-mCherry vector resulted in β-cell-targeted mCherry expression.
During antigen presentation, interactions between CTLA4 and B7 molecules or PD1 and PDL1 negatively regulate immune responses in a non-redundant manner ( Figure 1b ). We designed and synthesized an artificial, codon-optimized, PDL1-CTLA4Ig gene encoding both full-length PDL1 and CTLA4Ig proteins, conjugated with the T2A self-cleaving peptide linker. We cloned the PDL1-CTLA4Ig sequence, or the PDL1 open-reading frame alone, into pAAV-MIP2 vector ( Figure 1c ). Western blotting analysis with a specific anti-PDL1 antibody verified PDL1 expression, including unmodified 50 kDa and glycosylated 55 kDa proteins, from the Ins1 β-cell line, upon transfection with the two constructs ( Figure 1d ). CTLA4Ig expression was also verified by anti-CTLA4 antibody. We also generated an AAV vector expressing IL10 (AAV-IL10), which expressed the approximately 17-kDa IL10 protein upon transfection into Ins1 cells.
β-Cell-targeted PDL1-CTLA4Ig or IL10 expression blocked the development of autoimmune diabetes in NOD mice We injected 8-week-old NOD mice with the β-cell-targeted AAV8 vectors expressing PDL1 alone, PDL1-CTLA4Ig or IL10. Fasting blood glucose levels were monitored for 16 weeks postinjection. Mice with no treatment showed high incidences of hyperglycemia (seven out of the nine mice) ( Figure 2a ). Hyperglycemia onset was sudden and progressed rapidly, leading to marked weight loss, increased urine output, hunched back and rough coating. AAV8-PDL1 vector-treated mice showed delayed hyperglycemic development (Figure 2a ), seven out of the nine animals developed hyperglycemia by study termination. In contrast, the groups that received AAV8-PDL1-CTLA4Ig or AAV8-IL10 vectors showed significant protection from the development of autoimmunemediated diabetes; in both groups, only two out of the nine mice showed hyperglycemia (Figure 2a ). At study termination, we killed the mice and examined for pathological changes. Diabetic mice commonly showed a pale pancreas with minimal fat tissue. No notable changes were found in normoglycemic mice treated by AAV8-PDL1 or AAV8-PDL1-CTLA4Ig. However, all AAV8-IL10treated mice showed splenomegaly, as described previously in IL10-treated mice. 27 Immunohistochemistry was then performed to assess the levels of autoimmune destruction of β cells in control and treated mice. Pancreatic tissue sections at 16 weeks postinjection were stained for insulin and glucagon by specific antibodies. Untreated control mice showed notable destructive infiltration involving most of the islet area and excessive loss of β cells (Figures 2b and c ). Pancreatic IL10 overexpression showed similar peri-islet infiltration but with preserved β-cell mass ( Figures  2b-d ). AAV8-PDL1-CTLA4Ig treated animals showed no or minimal peri-islet immune infiltration with well-preserved β-cell mass (Figures 2b-d) . These data demonstrated that β-cell-targeted PDL1-CTLA4Ig overexpression can protect NOD mice from autoimmune diabetes through preserved β-cell mass. β-Cell-targeted PDL1-CTLA4Ig and IL10 expression reduced blood glucose levels in early-onset diabetic NOD mice Next, we assessed whether β-cell-targeted PDL1, PDL1-CTLA4Ig or IL10 expression could restore normoglycemia at early onset of autoimmune diabetes in NOD mice. Early-onset diabetic NOD mice, with over 200 mg dl − 1 blood glucose levels for 2 consecutive weeks, received intraperitoneal injection of AAV8 vectors at 2 × 10 13 genome copies per kg. All control, AAV8-IL10-, The effects of β-cell-targeted PDL1-CTLA4Ig expression on rejection of allo-islets grafts in MHC-matched recipient mice in the absence of autoimmunity against β cells The failure in normalizing blood glucose levels by PDL1-CTLA4Ig in the early-onset diabetes in NOD mice can be either due to a lack of sufficient immunosuppression or insufficient remaining β cells to achieve glucose level homeostasis. To assess the effects of PDL1-CTLA4Ig-mediated β-cell protection, with sufficient numbers of healthy islets, we used the MHC-matched islet transplant models. First, to assess the effects of PDL1-CTLA4Ig in the absence of autoimmunity, we used the allo-islet transplant model with drug-induced diabetes. Specifically, we induced diabetes in DBA2 mice by low dose, multiple intraperitoneal injections of streptozotocin (STZ). We also treated Balb/c mice with the AAV vectors expressing PDL1, PDL1-CTLA4Ig or IL10. Two weeks after AAV vector administration, we harvested pancreatic islets from Balb/c mice, which were then transplanted into the kidney capsules of the diabetic DBA2 mice. Fasting blood glucose levels were monitored for 16 weeks. As predicted, animals without grafts continued to show a progressive course of hyperglycemia due to STZ-mediated β-cell damage (Figure 4a , top panel). In contrast, untreated Balb/c islet cell grafts were able to ameliorate the hyperglycemic phenotype of DBA2 mice (Figure 4a ). However, this effect was transient, and DBA2 mice started to show an increase in their blood glucose levels 10-14 days posttransplantation (PT). At 16 weeks PT, all mice transplanted with unmodified allo-islets became hyperglycemic (mean fasting blood glucose level 4500mg dl − 1 , n = 5). PDL1-CTLA4Ig-expressing islet cell grafts were able to completely reverse the diabetes in STZ-treated DBA mice and protected this phenotype for 16 weeks PT in five out of the six mice (Po 0.05). Of note, unilateral nephrectomies of the kidney capsule grafts at 16 weeks PT rendered normoglycemic graft recipient mice hyperglycemic immediately after nephrectomy (Figure 4a, bottom panel) , verifying that normalized glucose levels were due to the islet grafts, rather than spontaneous recovery of endogenous pancreatic β cells. Although not statistically significant, one of three diabetic DBA mice, treated with IL10 expressing allo-islets, also showed reversal of hyperglycemia for 16 weeks (Figure 4a ).
β-Cell-targeted CTLA4Ig expression can lead to secretion of CTLA4Ig, with the potential to induce systemic immune suppression. We postulated that β-cell-targeted expression of the cell surfaceanchored, full-length CTLA4 could block the trafficking of B7 molecules in the endoplasmic reticulum of the islet cells, leading to their downregulation and protection of β cells. We therefore tested the utility of the full-length CTLA4, instead of CTLA4Ig, along with PDL1 (designated as AAV8-PDL1-CTLA4full). Expression of CTLA4 and PDL1 was verified by western blotting (Figure 4b ). Pretreatment of Balb/c allo-islets with the AAV vector expressing the PDL1-CTLA4full polyprotein showed complete reversal of hyperglycemia in one out of the five diabetic DBA2 mice (Figure 4c, no significance) . Intriguingly, one recipient mouse, which initially showed failed normalization of blood glucose levels, became normoglycemic 10 weeks PT. Again, unilateral nephrectomies of the two normoglycemic mice 16 weeks PT abrogated the therapy.
We then performed immunohistochemical analysis of the islet cell grafts at 16 weeks PT. Control, untreated Balb/c islets were almost completely destroyed by inflammatory cells in DBA2 mice, with detection of a paucity of insulin-positive cells (Figure 4d , top panels). In contrast, the DBA2 mice with reversed diabetes upon transplantation of PDL1-CTLA4Ig-or PDL1-CLTA4full-treated islets showed significant preservation of β cells and no infiltrative inflammatory cells (Figure 4d ). IL10-treated grafts showed a minimal degree of destructive inflammatory infiltration with significant preservation of insulin-positive β cells (Figure 4d ). β-Cell-targeted PDL1-CTLA4Ig expression transiently protects islet cell allografts from hyperacute rejection in the setting of autoimmune diabetes We repeated the previous experiment using ICR/HaJ mice as donors for islet cell grafts and autoimmune diabetic NOD mice as recipients. ICR/HaJ strain carries the same H2g7 MHC haplotype as NOD mice. ICR/HaJ mice do not develop insulitis or diabetes, thus allowing MHC-matched islet transplantation for NOD mice. When fasting blood glucose levels were monitored; control, untreated islet cell grafts exhibited transient reductions in blood glucose levels in two out of thee diabetic mice ( Figure 5 , top panel). Similarly, IL10-treated islets normalized hyperglycemia but only for 1 week. On the other hand, PDL1-CTLA4Ig-expressing islet cell grafts successfully reversed diabetes in NOD mice for 3 weeks (n = 3).
Pre-T1D is characterized by ongoing islet β-cell destruction in which sufficient β-cell mass and functionality remain to preserve glucose homeostasis. Silencing the diabetogenic attack at this stage could prevent full-blown diabetes. Recently, co-stimulation modulation with CTLA4Ig (abatacept) has demonstrated a slowing decline of β-cell function in recent-onset T1D. Notably, the decrease in β-cell function with abatacept parallels the placebo after 6 months, despite continued administration of abatacept 42 years. 23 Here we showed that combination blockade of two nonredundant immune inhibitory pathways, CTLA4 and PD1, in prediabetic NOD mice prevented T1D development through preserved β-cell mass. As reported previously, 28 β-cell-targeted IL10 overexpression also blocked T1D progression; however, Figure 2 . β-Cell-targeted PDL1-CTLA4Ig or IL10 expression blocked the development of autoimmune diabetes in NOD mice. (a) Female NOD mice were treated with the indicated AAV vectors and fasting blood glucose levels were monitored for 16 weeks. Fisher's exact test analysis indicated that AAV-IL10 and AAV-PDL1-CTLA4Ig treatments reduced the incidence of spontaneous diabetes (P o0.05). (b) Representative pancreatic islets of AAV8 vector-treated or control mice stained with anti-insulin (green) and anti-glucagon (red) antibodies. Nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole). (c) Islets with infiltrating cells in untreated and AAV-PDL1-CTLA4Ig-treated mice were stained for insulin and CD45 by specific antibodies. (d) Insulin-positive β cells in whole pancreatic sections were visualized by anti-insulin antibody (representative images from control-, AAV-IL10-and AAV-PDL1-CTLA4Ig-treated mice), and the percentage of β-cell areas were compared between the treatments (n = 3 each). *Po 0.05, Student's t-test. treated mice showed notable splenomegaly, which was also reported in a previous study using IL10 gene therapy. 27 Similarly, in an allo-islet transplantation model, pretreatment of Balb/c islets to express PDL1-CTLA4Ig, and a lesser degree with IL10 or PDL1-CTLA4full expression, is sufficient to protect acute rejection of alloislet grafts in STZ-induced diabetic DBA2 mice, leading to longterm allo-graft survival in the absence of systemic immunosuppressive regimen. Our results therefore demonstrate the potency of immunosuppressive effects by simultaneous blockade of CTLA4 and PD1 pathways, a plausible therapeutic intervention for pre-T1D.
In sharp contrast to the successful β-cell protection in the settings with no preexisting autoimmunity to β cells, β-celltargeted overexpression of PDL1-CTLA4Ig or IL10 genes in the early-onset diabetes failed to reverse hyperglycemia in NOD mice. Moreover, although PDL1-CTLA4Ig expression facilitated extended allo-islet grafts survival in autoimmune diabetic mice, the protective effect was transient and the mice relapsed in hyperglycemia 4 weeks after islet transplantation. Those observations indicate that the simultaneous suppression of the PD1 and CTLA4 axes can block the development of autoimmunity, or adaptive immunity in the case of islet transplantation, to β cells but is ultimately insufficient for reversing fully activated β-cell-targeted immunity. It is possible that additional therapies, such as low dose anti-CD3 treatment and transient exogenous insulin therapy, may be required at this stage of disease. These auxiliary therapies would support the immunosuppressive effects of PDL1-CTLA4Ig while reducing the stress of β cells due to prolonged hyperglycemia. Nevertheless, our data highlight the challenges in controlling established autoimmunity through β-cell-targeted immuno-modulatory gene therapy. In this context, it is notable that treatment with both PDL1-CTLA4Ig-and IL10-expressing AAV vectors led to reduced hyperglycemia in diabetic NOD mice. Unexpectedly, however, this combination therapy failed to control weight loss even though treated mice showed overall improvement, including a healthy appetite, smooth coat and better preserved β-cell mass. Further studies are necessary to understand the underlying mechanism for weight loss. As NOD mice also have the highly unique, autoimmunitysusceptible genetic background, 29 it is plausible that β-cell-targeted immunotherapy was not sufficient to control other spontaneous autoimmune diseases in NOD mice, such as Sjorgren's syndrome.
Initially, we speculated that the failure in normalizing blood glucose levels by the PDL1-CTLA4Ig gene therapy approach in the early-onset diabetes might be due to insufficient remaining β cells to achieve glucose level homeostasis. However, we observed comparable results with the genetically modified islet transplantation approach. Both AAV vectors expressing IL10 or PDL1-CTLA4Ig showed clear therapeutic effects in the setting of no preexisting auto-immunity to β cells but not after the onset of autoimmune diabetes. Thus immuno-modulatory therapies with PDL1-CTLA4Ig or IL10 are not sufficient to block established autoimmune diabetes, either in the gene therapy or in the gene and cell therapy settings. In addition, apart from splenomegaly in mice treated with IL10-expressing AAV vectors, we found no notable differences between the AAV-PDL1-CTLA4Ig and AAV-IL10 groups. It is possible that marked intra-group variations in the timing of autoimmune diabetes onsets and severity of immune infiltration among individual NOD mice might have masked the differences between the two treatments. Further studies with increased numbers of mice and analyses of β-cell-infiltrating/recruited immune cells may provide better mechanistic insights into the therapeutic effects between IL10-and PDL1-CTLA4Ig-mediated therapies.
In conclusion, our data demonstrate the potent immunosuppressive effects of β-cell-targeted PDL1-CTLA4Ig overexpression against T1D development and allo-islet rejection. The gene-based simultaneous inhibition of PD1 and CTLA4 pathways would provide a unique strategy for immunosuppression-free tissue/organ transplantation, especially in a setting without established autoimmunity.
MATERIALS AND METHODS
Mice All studies were approved by the Mayo Clinic Institutional Animal Care and Use Committee. Six-week-old BALB/CJ, DBA/2J, ICR/HaJ and NOD/ShiLtJ mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). Mice were maintained under a 12-h lightdark cycle and were provided with irradiated Rodent Laboratory Chow (Purina 5053, Wilkes-Barre, PA, USA). Fasting (4-6 h) blood glucose levels were monitored weekly or bi-weekly by FreeStyle Lite Blood Glucose Monitor (Abbott Laboratories, Abbott Park, IL, USA). Mice received AAV8 vectors at a final dose of approximately 2 × 10 13 genome copies per kg.
Cells
HEK293T cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% calf serum, 50 U ml − 1 penicillin and 50 μg ml − 1 streptomycin. Cells were kept at 37°C with 5% CO 2 .
Plasmids
The codon-optimized, PDL1-CTLA4Ig or PDL1-CTLA4 fusion constructs were synthesized by GenScript (Piscataway, NJ, USA). The PDL1 and CTLA4Ig (or CTLA4) open-reading frames are linked by the T2A selfcleaving peptide linker. The 1.13-kbp MIP2 region was PCR amplified from mouse genomic DNA with primers Forward Mlu1, 5′-GCCA CACGCGTCCCTCCTCTTGCATTTCAAAT-3′ and Reverse BamH1, 5′-TCC ACAGGATCCTGTTGAAACAATAACCTGGAA-3′. pAAV-MIP2-Luciferase vector was generated through cloning the MIP2 promoter sequence into the Mlu1-BamHI sites of pAAV-CMV-Luc vector, while pAAV-MIP2-eGFP (enhanced green fluorescent protein) vector was generated by replacing the luciferase gene in the pAAV-MIP2-Luciferase with the emerald GFP gene. pAAV-MIP2-PDL1, pAAV-MIP2-PDL1-CTLA4Ig and pAAV-MIP2-PDL1-CTLA4 vectors were generated by replacing the emerald GFP transgene with PDL1, PDL1-CTLA4Ig and PDL1-CTLA4 by utilizing the unique restriction sites BamH1 and Xho1. pAAV-mRIP vector was previously described. 24 IL10 cDNA was cloned into this vector plasmid, resulting in pAAV-mRIP-IL10.
AAV8 vectors
The AAV8 vector stocks were produced in human 293T cells using the helper-free three-plasmid transfection method and titrated as described previously, 24 with modification of the use of AAV8 capsid-expressing plasmid pRC-2/8 (kindly provided by Dr James Wilson through National Gene Vector Biorepository).
Detection of protein expression
To verify the expression of the AAV8 delivered transgene(s), 293T cell lysates, transfected with either pAAV-mRIP-IL10 or pAAV-MIP2-PDL1-CTLA4Ig, were used for immunoblotting with anti-IL10 (Abcam, Cambridge, MA, USA, JES5-2A5) and anti-PDL1 (goat antimouse B7-H1, R&D Systems, Minneapolis, MN, USA) antibodies.
Immunohistochemistry staining
Seven-μm cryo-sections of Optimal Cutting Temperature (Sakura, Torrance, CA, USA)-embedded pancreatic tissues and left kidneys with grafts were immediately fixed in 4% paraformaldehyde, permeabilized with phosphate-buffered saline containing 0.3% Triton-X for 10 min and blocked in phosphate-buffered saline containing 5% fetal bovine serum. Sections were incubated with Guinea Pig anti-insulin and mouse anti-glucagon antibodies (Dako, Carpinteria, CA, USA), followed by confocal microscopy with either Zeiss LSM 510 or Zeiss LSM 780 (Zeiss, San Diego, CA, USA). STZ administrations STZ was prepared in Hank's Balanced Salt Solution (Sigma, St Louis, MO, USA). DBA2 mice received approximately 50 mg kg − 1 STZ through intraperitoneal injection in five consecutive daily doses.
Islets isolation and culture Two weeks after AAV8 vectors administration, mice were killed and pancreatic islets were isolated through perfusion and digestion of the pancreas with collagenase V (Sigma) as described. 30 Untreated islets were also prepared from untreated age-matched mice.
Islets culture and transplantation Isolated islets were cultured for 4-5 days to enhance healing in glucose adjusted (25 mM D-glucose) RPMI medium supplemented with 10% calf serum, 50 U ml − 1 penicillin, and 50 μg ml Figure 3 . β-Cell-targeted PDL1-CTLA4Ig and IL10 expression reduced blood glucose levels in early-onset diabetic NOD mice. (a) Fasting blood glucose levels in female NOD mice were monitored to detect early-onset hyperglycemia. Mice were then treated with the indicated AAV vectors and were further monitored for the blood glucose levels and body weights. (b) Representative pancreatic islets of the mice showing reduced blood glucose levels are shown. Islets were stained with anti-insulin (green) and anti-glucagon (red) antibodies. Nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole).
streptomycin, in non-sticking Petri dishes at 28°C with 5% CO 2 . High-quality islets were manually picked and counted. Each animal received approximately 350 IE (Islet Equivalent) units. Islets were grafted in a pocket under the left kidney capsule as described by Zmuda et al. 30 Fasting blood glucose levels were monitored weekly or bi-weekly. One hundred and twenty days PT, Figure 4 . The effects of β-cell-targeted PDL1-CTLA4Ig expression on rejection of allo-islets grafts in MHC-matched recipient mice in the absence of autoimmunity against β cells. (a) STZ-treated DBA2 mice, transplanted with genetically modified Balb/c mouse islets, were monitored for fasting blood glucose levels. At 16 weeks after islet transplantation, unilateral nephrectomy was performed to remove the islet grafts to see the recurrence of hyperglycemia. (b) Western blotting analysis was performed to verify the expression of PDL1 and CTLA4 using β-cell line (Min6 cells) transfected with pAAV-PDL1-CTLA4-full plasmid. (c) Same as panel (a), except the islets were modified to express the PDL1-CTLA4full protein. (d) Representative images of recovered islet grafts in the renal capsules are shown. Islets were stained with antiinsulin (green) and anti-glucagon (red) antibodies. Nuclei were counterstained with DAPI (4,6-diamidino-2-phenylindole).
nephrectomies were performed to harvest the grafts. Blood glucose levels were monitored for 2 weeks after removal of grafts.
Sample size and statistical analysis
For β-cell mass analysis, groups were compared by unpaired Student's t-test, and data were presented as means ± s.e.m. Significance was accepted for P o 0.05. For the incidence of spontaneous auto-immune diabetes or reversal of hyperglycemia, data sets were analyzed by Fisher's exact test, and significance was accepted for P o0.05. Figure 5 . β-Cell-targeted PDL1-CTLA4Ig expression transiently protects islet cell allografts from hyperacute rejection in the setting of autoimmune diabetes. Autoimmune diabetic NOD mice received genetically modified ICR/HaJ mouse islets and were monitored for fasting blood glucose levels.
